Activity of single agent vinorelbine in pretreated non-Hodgkin's lymphoma.
BACKGROUND
To assess the activity of single agent vinorelbine in pretreated non Hodgkin's lymphoma.


METHODS
Twenty-three pretreated patients with non-Hodgkin's lymphoma (14 intermediate-high grade, nine low-grade) were treated with vinorelbine 30 mg/m2/week for six months or up to four doses after achieving CR.


RESULTS
Among 13 evaluable patients with intermediate-high grade lymphoma, three obtained CR and three PR, for an overall response rate of 46% (95% CI: 19%-75%). Median duration of response was six months. Otherwise, vinorelbine did not show any significant activity inn chemotherapy-refractory low-grade non-Hodgkin's lymphoma. Toxicity was acceptable, and the drug was well-tolerated even in elderly patients.


CONCLUSIONS
The good activity and tolerability of vinorelbine in relapsed intermediate-high grade lymphoma suggest its inclusion in first-line regimens, especially in elderly patients.
Balzarotti
M
M
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
Santoro
A
A
Tondini
C
C
Fornier
M
M
Bonadonna
G
G
D000328:Adult; D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy*; D008875:Middle Aged; D016879:Salvage Therapy; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
D000972:Antineoplastic Agents, Phytogenic; D014747:Vinblastine; D000077235:Vinorelbine